Codexis Announces Enhanced Strategic Focus and Extends Projected Cash Runway to Mid-2026
Highly customized biocatalysts can transform API manufacturing processes by eliminating steps, increasing yield, and reducing solvent usage and waste. Explore novel approaches that benefit the triple bottom line – social, environmental, and financial.
Highly customized biocatalysts can transform API manufacturing processes by eliminating steps, increasing yield, and reducing solvent usage and waste. Explore novel approaches that benefit the triple bottom line – social, environmental, and financial.
When manufacturing RNA for therapeutic applications, the process ideally delivers high yields and minimizes unwanted byproducts, while being economically sound. Engineered enzymes can overcome the particular obstacles faced in the production of quality RNA at commercial scale.
When manufacturing RNA for therapeutic applications, the process ideally delivers high yields and minimizes unwanted byproducts, while being economically sound. Engineered enzymes can overcome the particular obstacles faced in the production of quality RNA at commercial scale.
Held on March 28, 2023, scientists from Codexis and Tune Therapeutics presented how engineered enzymes can overcome common challenges with capping efficiency and dsRNA impurities in IVT manufacturing of mRNA required for vaccines and cell/gene therapeutics.
Watch now